Since the industrial revolution, there has been a collective Western consensus that technology would continue to propel our world forward, further strengthening our personal and professional lives.

The first cancer cell therapies were personalized treatments made by isolating and engineering a patient’s own T cells in the lab—a complex, cumbersome, and expensive process. A slew of companies are ...

Bristol Myers Squibb has agreed to settle a lawsuit with two employees who were fired for refusing to get COVID-19 vaccines. The employees, Jeremy Beer and John Lott, filed a lawsuit in December 2021 ...

Pharmaceutical giant Bristol Myers Squibb has been quietly growing in the Seattle area. Since acquiring Celgene and its Seattle operations two years ago, BMS now has more than 1,240 employees in the ...

Patients undergoing a bone marrow or stem cell transplant face the prospect of a dangerous and potentially fatal immune response. The FDA has approved Bristol Myers Squibb drug Orencia as a way to ...

Despite coming to market second, Bristol Myers Squibb’s Mirati Therapeutics-inherited cancer med Krazati has gained the lead on its Amgen rival Lumakras in a heated KRAS race. Late Friday, the U.S.

Bristol Myers Squibb Co. (BMS) has terminated its $1.3 billion-plus deal for Agenus Inc.’s anti-TIGIT bispecific antibody AGEN-1777 as part of a promised belt-tightening. In May 2021, BMS paid Agenus ...